OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cell-free expression shows promise in preclinical applications but presents scale-up challenges.
Demand for recombinant microorganism-based cell culture supplements.
September 02, 2021
Advancements in bioprocessing technologies test microbial fermentation adaptability.
August 02, 2021
The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.
July 22, 2021
Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.
July 09, 2021
The collaboration continues as the companies design bioprocess impurity reagent sets to detect residual HCP from HEK 293 cells.
July 01, 2021
The acquisition of Intermountain Life Sciences will double Cytiva’s capacity for buffers and liquid cell culture media at its manufacturing site in Logan, Utah.
June 02, 2021
Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.
May 19, 2021
VectorY, a Netherlands-based biotechnology company, has been selected as the European winner of MilliporeSigma’s 2021 Advance Biotech Grant Program.
May 02, 2021
Demand for recombinant microorganism-based cell culture supplements is rising on the back of lower contamination risk.
April 02, 2021
Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.
The innovation of single-use technologies is applicable early on in the manufacturing process.